Morchella polysaccharide ameliorates myocardial infarction inflammation in mice through increasing gut microbiota-derived 12-HEPE
Abstract
Myocardial infarction (MI) initiates robust inflammatory responses. While moderate inflammation facilitates the clearance of necrotic debris, sustained inflammation promotes fibrosis and exacerbates MI progression. Fungal polysaccharides have shown significant anti-inflammatory activity, but role of Morchella polysaccharide (MCP) in modulating MI-associated inflammation remains unclear. In this study we investigated whether MCP ameliorated myocardial infarction injury and elucidated the underlying mechanisms focusing on the gut microbiota and associated metabolites. MI mice were established in mice by permanent ligation of the left anterior descending (LAD) coronary artery. MCP (200, 600 mg·kg−1·d−1. i.g.) was administered daily from D7 prior-MI induction and continued for 3 or 7 days post-MI. We showed that MCP administration significantly alleviated cardiac inflammation in post-MI mice. Metabolite screening identified 12-hydroxy-eicosapentaenoic acid (12-HEPE) as a critical mediator of MCP’s anti-inflammatory effects. Intestinal metabolomic screening revealed that MCP markedly upregulated the abundance of the beneficial genus Lactobacillus. Eliminating the intestinal flora using a broad-spectrum antibiotic cocktail for 2 weeks abolished MCP-induced 12-HEPE elevation and anti-inflammation in post-MI mice. On the other hand, direct supplementation of 12-HEPE (200 µg·kg−1·d−1, i.p.) beginning 7 days prior to MI induction attenuated the inflammation. In conclusion, this study reveals that MCP attenuates post-MI inflammation by enriching beneficial gut bacteria such as Lactobacillus and increasing their metabolite 12-HEPE.